J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davit, B
Right arrow Articles by Lesko, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davit, B
Right arrow Articles by Lesko, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling

B Davit, K Reynolds, R Yuan, F Ajayi, D Conner, E Fadiran, B Gillespie, C Sahajwalla, SM Huang, and LJ Lesko

Recent advances in in vitro metabolism methods have led to an improved ability to predict clinically relevant metabolic drug-drug interactions. To address the relationships of in vitro metabolism data and in vivo metabolism outcomes, the Office of Clinical Pharmacology and Biopharmaceutics in the Center for Drug Evaluation and Research, Food and Drug Administration, evaluated a number of recently approved new drug applications. The goal of these evaluations was to determine the contribution of in vitro metabolism data in (1) predicting in vivo drug-drug interactions, (2) determining the need to conduct an in vivo drug-drug interaction study, and (3) incorporating findings into drug product labeling. Ten cases are presented in this article. They fall into two major groups: (1) in vitro data were predictive of in vivo results, and (2) in vitro data were not predictive of in vivo results. Discussion of these cases highlights factors limiting predictability of in vivo metabolic interactions from in vitro metabolism data. The integration of these findings into drug product labeling is also discussed.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
A. Ogasawara, T. Kume, and E. Kazama
Effect of Oral Ketoconazole on Intestinal First-Pass Effect of Midazolam and Fexofenadine in Cynomolgus Monkeys
Drug Metab. Dispos., March 1, 2007; 35(3): 410 - 418.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Y. Chien, A. Lucksiri, C. S. Ernest II, J. C. Gorski, S. A. Wrighton, and S. D. Hall
STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE
Drug Metab. Dispos., July 1, 2006; 34(7): 1208 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Petri, E. Bergman, P. Forsell, M. Hedeland, U. Bondesson, L. Knutson, and H. Lennernas
FIRST-PASS EFFECTS OF VERAPAMIL ON THE INTESTINAL ABSORPTION AND LIVER DISPOSITION OF FEXOFENADINE IN THE PORCINE MODEL
Drug Metab. Dispos., July 1, 2006; 34(7): 1182 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. L. Walsky, R. S. Obach, E. A. Gaman, J.-P. R. Gleeson, and W. R. Proctor
SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY MONTELUKAST
Drug Metab. Dispos., March 1, 2005; 33(3): 413 - 418.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. L. Walsky and R. S. Obach
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Drug Metab. Dispos., June 1, 2004; 32(6): 647 - 660.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S.-M. Huang and L. J. Lesko
Drug-Drug, Drug-Dietary Supplement, and Drug-Citrus Fruit and Other Food Interactions: What Have We Learned?
J. Clin. Pharmacol., June 1, 2004; 44(6): 559 - 569.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
H. Zhou, Z. Tong, and J. F. McLeod
"Cocktail" Approaches and Strategies in Drug Development: Valuable Tool or Flawed Science?
J. Clin. Pharmacol., February 1, 2004; 44(2): 120 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama
Impact of Drug Transporter Studies on Drug Discovery and Development
Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Ito, D. Hallifax, R. S. Obach, and J. B. Houston
IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM
Drug Metab. Dispos., June 1, 2005; 33(6): 837 - 844.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Clinical Pharmacology